ArticlePloS one2025
Brachial-ankle pulse wave velocity predicts liver volume in patients with autosomal dominant polycystic kidney disease.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and Polycystic liver disease (PLD) is the most common extrarenal manifestation of ADPKD. Various non-inherited factors have been reported to affect total kidney volume (TKV) in ADPKD. However, the non-inherited factors affecting liver volume (LV) in ADPKD are unknown.
methodsWe aimed to identify the factors affecting LV and TKV in ADPKD; and to analyze the relationship between changes in these parameters and arterial stiffness, assessed using brachial-ankle pulse wave velocity (baPWV).
resultsWe enrolled 165 patients (66 men and 99 women; mean age 47.3 ± 6.9 years). Univariable analysis revealed that sex, mean baPWV, ΔbaPWV, tolvaptan use, hyperlipidemia, hyperuricemia, Hb concentration, eGFR, proteinuria, and height-adjusted TKV (htTKV) were significantly associated with height-adjusted LV (htLV) at baseline. Multivariate analysis showed that sex, BMI, ΔbaPWV, and tolvaptan use were significantly associated with htLV at baseline. The baseline htLV correlated with ΔbaPWV (r = 0.32, p < 0.0001). Univariable linear mixed model analysis revealed that sex, mean baPWV, ΔbaPWV, tolvaptan use, hyperuricemia, Hb concentration, eGFR, and proteinuria significantly affected the change in htLV. Multivariate linear mixed model analysis revealed that sex, BMI, and tolvaptan use significantly affected the change in htLV. The change in the htLV ratio was larger in patients with a higher ΔbaPWV (p < 0.0001). Whereas, ΔbaPWV was not a significant factor for the baseline htTKV and the changes in htTKV in univariable and multivariable analysis.
conclusionsWe have shown that ΔbaPWV is a predictor of baseline htLV, and the chronological changes in htLV in patients with ADPKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.